News Center - View Videos, Articles, & Resources

Featured Articles

Hear from Prothenians as they share their perspectives on what Rare Disease Day means to them

March 14, 2023

Q&A with Prothena’s Ansgar Conrad answers questions about the company’s partnership with ASPIRE

February 23, 2023

Q: What is ASPIRE? A: The Amyloidosis Stakeholder Partnerships for Impact Reach and Equity (ASPIRE) is a collaborative of biotech and pharmaceutical companies committed to improving diagnosis, systems of care, and health equity for patients suffering from amyloidosis, a rare disease caused by protein build-up. Q: What is ASPIRE’s goal? A: ASPIRE aims to accelerate […]

The impact of AL amyloidosis on work outcomes

January 23, 2023

Light chain (AL) amyloidosis is a rare and progressive disease that interferes with normal organ function and lead to failure of vital organs, like the heart. Currently, there are no approved therapies that significantly improve survival. The impact of amyloidosis goes beyond health. Patients with AL amyloidosis experience frequent overall loss of productivity, missed work […]

Press Releases

Date	Title
Mar 21, 2023	Prothena to Participate in Stifel 2023 Virtual CNS Days
Mar 14, 2023	Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting
Feb 23, 2023	Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights
Feb 16, 2023	Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
Feb 03, 2023	Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 31, 2023	Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease
Dec 14, 2022	Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares
Dec 13, 2022	Prothena Announces Proposed Public Offering of Ordinary Shares
Dec 12, 2022	Prothena Presents Data Demonstrating Consistent Survival Benefit Observed With Birtamimab In Mayo Stage IV AL Amyloidosis Patients In Phase 3 VITAL Study At ASH 2022
Nov 21, 2022	Prothena Announces Achievement Of $40 Million Clinical Milestone Payment From Novo Nordisk For PRX004/NNC6019 Under Investigation For The Treatment Of ATTR Cardiomyopathy